NOTCH1 and acute lymphoblastic leukemia: Moreover, T-ALL cell lines expressing leukemogenic NOTCH1 HD domain mutations were more sensitive to the SERCA inhibitor thapsigargin than normal receptors, supporting the possibility of a therapeutic window for compounds of this class (40).